Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Encorafenib and Binimetinib in Stage IIB/C Melanoma
NCT05270044Phase 3Active, not recruiting
- Sponsor
- Pierre Fabre Laboratories
- Start
- May 2022
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, triple-blind trial in cutaneous melanoma (CM) comparing Encorafenib + Binimetinib with Placebo (2 arms). Primary endpoint: Recurrence-Free Survival at 4.4 years. Started May 2022; status: active, not recruiting.
02
Drugs
encorafenibbinimetinib
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT05270044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05270044.